Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1589-1590

  Demarles, D ^a   Gillotin, C ^a   Bonaventure Paci, S ^a   Vincent, I ^a   Fosse, S ^a   Taburet, A M ^a  

^a GLAXOSMITHKLINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG INTERACTION; FEMALE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; BEVERAGES; CARBAMATES; CITRUS; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; SULFONAMIDES;

EID: 0036236067     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1589-1590.2002     Document Type: Article

References (6)

1. Grapefruit juice-drug interactions
2. Simple high performance liquid chromatography determination of the protease inhibitor indinavir in human plasma
3. The use of nonparametric methods in the statistical analysis of the two period change-over design
4. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
5. In vivo effect of α1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
6. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults